Curriculum Vitaes
Profile Information
- Affiliation
- Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo, JapanVisiting Research Scientist, Laboratory for Pharmacogenomics, RIKEN, Yokohama, JAPANDepartment of Statistical and Translational Genetics, Center for Genomic Medicine, Fujita Health UniversityVisiting Research Scientist, Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan
- Degree
- MD(Shimane University, Japan)PhD(Apr, 2020, Yokohama City University, Japan)
- Researcher number
- 10789580
- ORCID ID
https://orcid.org/0000-0002-4852-2401- J-GLOBAL ID
- 201901008820546985
- researchmap Member ID
- B000373995
Research Interests
4Research Areas
2Research History
10Committee Memberships
2Awards
10Papers
40-
Communications Biology, Sep 30, 2026 Peer-reviewed
-
Nature Communications, Aug 8, 2026 Peer-reviewed
-
Molecular Psychiatry, May, 2026 Peer-reviewed
-
Nature Genetics, Apr 20, 2026 Peer-reviewed
-
Clinical pharmacology and therapeutics, Apr 14, 2026 Peer-reviewed5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).
Professional Memberships
8Research Projects
7-
Grant-in-Aid for Young Scientists, Grant-in-Aid for Early-Career Scientists, Japan Society for the Promotion of Science, Apr, 2026 - Mar, 2029
-
Japan Research Foundation for Clinical Pharmacology, 2025 - 2027
-
Grant-in-Aid for Young Scientists, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2024
-
Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2021 - Mar, 2024
-
Japan Research Foundation for Clinical Pharmacology, 2022 - 2024
-
Japan Research Foundation for Clinical Pharmacology, 2021 - 2023
-
Incentive Research Projects, RIKEN, 2019 - 2021